We're essentially in the same place. I've invested more in NWBO than any other stock I've ever bought, but with the buyout IMGN is worth much more than NWBO.
Something I do believe that all of us need to do when discussing future prices, look at the Market Cap. I'd make the assumption that 1.5 billion shares are outstanding. IE a $20 share price represents a $30 billion market cap. While that may sound high, a billion in earnings could give that with a P/E of 30, certainly a possibility, or it would take $3 billions in earnings at a P/E of 10. I frankly believe that in time our earnings will go to tremendous numbers of billions, but it doesn't happen instantaneously.
If we're not bought out, and when we gain a tumor agnostic label, I've got to believe our sales will quickly go into double to triple digit billions, earnings will certainly go into double digits, for purposes of discussion let's say we reach $30 billion in earnings and lets say we're still at 1.5 billion shares. That's $2 a share, P/E or 10, $20 share price, P/E of 30, $60 share price. I believe that we'll justify that P/E of 30, but it can't be taken for granted. All that I'm suggesting is that earnings take time to grow, but our potential, with a tumor agnostic label, is almost unlimited over time, a trillion dollar market cap in a decade wouldn't be out of the question if anywhere near half of all solid tumor patients are getting one of the DCVax's. If we remain independent, just give it time. If we're bought out after a tumor agnostic label, but not that much in earnings, it ought to be at least $30 billion, or $20 a share, and it ought to be more than that.
Gary
